产品
编 号：F460082
分子式：C19H17NO5
分子量：339.34
分子式：C19H17NO5
分子量：339.34
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 78967-07-4
产品详情
生物活性：
Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC50 of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC50 of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities.
体内研究：
Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice.Animal Model:Female ddY mice (4 week old, 18-27 g) injected with phenyl-p-benzoquinone (PQ)
Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration:Oral administration; once
Result:Dose-dependently suppressed the writhing induced by PQinjection in mice.
体外研究：
Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay. Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.
Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC50 of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC50 of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities.
体内研究：
Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice.Animal Model:Female ddY mice (4 week old, 18-27 g) injected with phenyl-p-benzoquinone (PQ)
Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
Administration:Oral administration; once
Result:Dose-dependently suppressed the writhing induced by PQinjection in mice.
体外研究：
Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay. Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备